Our Review Summary
The American Academy of Neurology has set new guidelines for correctly diagnosing most strokes, recommending a type of MRI over a CT scan. The study, a literature review of MRI and CT studies going back to 1966, was published in the academy’s journal, Neurology. The story, however, does not make it clear how much better the MRI performs nor how much a switch to MRIs nationwide would cost. It does do a good job, though, of finding voices critical of the practicality of such a switch.
Why This Matters
Strokes are among the leading causes of death and injury, although this story doesn’t point this out. Correctly assessing a stroke can make a big difference in how someone is treated and whether a future stroke is prevented. At the same time, MRIs typically cost more and take longer than CT scans. To show whether they are worth the additional time and money, reporting about these new guidelines needs to quantify the benefits, potential harms and costs.
Criteria
Not Satisfactory
There is no mention in this story of costs, which is a shame. CTs are the preferred diagnostic tool right now and, apparently, are widely used. A switch to MRIs would not only mean the purchasing of a lot of new equipment but also staff training, new protocols and new drugs and dyes to be administered. Are we talking about an extra $1,000 per person? $5,000? More? The reporter spoke with two local medical institutions and could have asked both of them what it costs to buy both sets of equipment and what it costs to administer the exams.
Not Satisfactory
There are considerable benefits to be had, presumably. Because the number of patients is so huge, even a small improvement over present diagnositic techniques could have a big impact. As the study itself points out, "Presently, the only specific, approved therapy for acute ischemic stroke is IV tissue plasminogen activator (tPA) given within 4.5 hours. tPA use has been limited due to the short treatment window, concerns about the limitations of CT-based diagnosis, and fear of hemorrhagic risks." Does the story get into this, though? No. There is no attempt to quantify the benefits.
Not Satisfactory
There is almost a throw-away line in the study that says, " A recent study estimated the epidemiologic impact of DWI-based diagnosis would result in reduced annual TIA incidence (33%) and increased stroke incidence (7%) in the United States." Reducing these "mini-strokes" by 33% would indeed be a dramatic change, given the number of people who suffer from them, but these are "warning strokes," that can actually force people to change risky behaviors or begin taking the right medications to avoid an actual stroke. Those strokes may have actually climbed by 7% in the theoretical model of a world where diffusion scans were the norm. A 7% increase in strokes could mean an additional 55,650 people suffering a stroke each year, by our count. Again, these numbers would be nice to see in the story.
Not Satisfactory
Stating that something "is superior" and "is considerably better" is not quantifying potential benefits. The study itself spends little time on the numbers, but the numbers are there. And the reporter could have asked the authors to go through the numbers. There is no evidence presented that a strategy that starts with MRI has better outcomes than a strategy started with a CT. The guideline expert implies that it is obvious. The other doctors question that, but never explicitly in terms of outcomes. That’s where this story really falls short.
Not Applicable
Not applicable. There was no disease mongering in this story because the scope of the disease was never explained. As the actual study states, "Stroke is the third leading cause of death and the leading cause of permanent disability and disability-adjusted loss of independent life-years in Western countries." So a better way of diagnosing a stroke could have a huge impact. That sort of context should have been in the story.
Not Satisfactory
The story does use some independent sources, but it does not identify conflicts of interest. Again, this is a big missed opportunity because the authors of this paper have potential conflicts. They have worked with many drug and device makers, including Siemens, one of the big MRI makers, as well as: Boehringer Ingelheim, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Sanofi, Solvay Pharmaceuticals, GlaxoSmithKline, Wyeth, Genentech, LifeCycle Pharma A/S, ReNeuron, Novovision, NeuroLogica Corporation, Avanir Pharmaceuticals, Micromedex, AstraZeneca, Bayer Schering Pharma, Takeda Pharmaceutical Company Limited, Embrella Cardiovascular, Millennium Pharmaceuticals, Novo Nordisk, Otsuka Pharmaceutical Co., Pfizer, Mitsubishi Tanabe Pharma Corporation, PDL BioPharma, Inc., Terumo Neurovascular Monitoring, Guidant, Cordis, Bard Peripheral Vascular, Inc., Abbott, Boston Scientific, Olea Medical, Lantheus Medical Imaging, and, believe it or not, even more. Two hold patents on MR devices. Might they stand to beneft?
Not Satisfactory
This should have been the entire point of the story, but there is really no comparison. Just broad statements made about MRIs being superior, etc.
Satisfactory
This is something that the story really should have done high up. Why has it become standard practice to do a CT scan and not an MRI? One of the authors says that 40% of his time is spent giving MRIs and 40% doing CT scans. Is that typical? Nonethless, we’ll give it the benefit of the doubt.
Satisfactory
The story makes it clear that both approaches are available (and therefore not new), but it should have made it more clear how rare (or not) diffusion MRI is.
Satisfactory
There is a press release, but this story goes beyond the release.
Total Score: 3 of 9 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like